The infection with the Cytomegalovirus (CMV) is a prevalent herpes virus infection, with various symptoms that occur worldwide in individuals of all ages. Virus exposure can lead to lytic infection, resulting in symptoms ranging from common cold to more severe morbidity, including hepatitis and pneumonitis. Infection with cytomegalovirus (CMV) is a transmissible and readily susceptible body fluid such as urine, saliva, blood, milk in the breast and semen. The infection can spread rapidly from individuals infected with CMV with virus in their body fluids from urine or saliva. During delivery, the disease may spread from pregnant to child. The other way to transmit the disease is organ transplantation and blood transfusion. Cytomegalovirus treatment industry is primarily driven by increased incidence of CMV diseases, increased awareness of herpes disease, pipeline drugs that are promising by important players in the industry to treat CMV infection. In the United States, the prevalence of CMV is higher than in the Europe and Japan. In the coming years, the overall incidence and amount of diagnosed instances for CMV diseases are projected to grow modestly. Roughly 0.5 billion cases of CMV were recorded in 2016. In addition, increased public assistance and healthcare infrastructure development are expected to boost the growth of the market for therapy for CMV infection.
The development of the market will also be propelled by enhancing R&D projects for cytomegalovirus medicines by multiple companies. The major players operating in this market are ViroPharma, Chimerix, Inc., Vical, Inc., AiCuris Anti-infective Cures GmbH, Merck & Co., Inc., GlaxoSmithKline plc, F. Hoffmann-La Roche AG among others. Market players are investing strongly in R&D to develop new therapies and medications to treat infection with cytomegalovirus. In addition, healthcare regulatory bodies are paying more attention to new drugs by offering the drugs quicker approvals and unique status. Merck & Co, for example. Inc. has created antiviral drug Letermovir to treat CMV infection. The drug got fast track status from the U.S. FDA and the European Medicines Agency’s orphan drug status.
Market Dynamics: Drivers, Restraints, Opportunities Challenges
- High prevalence, CMV Infection will propel the market.
The CMV is associated with viruses that cause varicose veins and mononucleosis (mono) infectious. CMV is America’s most prevalent infectious cause of birth defects. Approximately 1 out of 5 children with congenital CMV infection will have birth defects or other long-term health issues such as hearing loss, Vision loss, Seizures, Microcephaly (small head) and other. Around 50% to 80% of adult population in the U.S. had an infection with CMV by age 40. Once CMV is in the body of a person, it will remain there for life. Thus the augmenting prevalence of CMV is anticipated to boost the market growth during the forecast period
- Need of novel therapies will serve an great opportunity for market player
The CMV Infection market is flooded with generic products even after such a large incidence as the patent loss of top-selling drugs in recent years. The latest off-patent drug was Valcyte, for which patent was lost in the Europe and United States in 2015 and 2013 respectively. With the expected launch of first-in-class CMV treatment and prophylaxis products, including cellular immunotherapy and a CMV vaccine, important changes in the CMV sector are expected to occur during the forecast period. The rise in market size due to the rise in the patient pool for CMV infection and the anticipated introduction of one novel vaccine: ASP0113 and Quinazoline -based inhibitor in near future.
Cystitis Market by Drug Type
Cystitis Market by Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Asia Pacific is anticipated to show lucrative growth, while North America holds the leading market share in terms of revenue during the forecast period.
Due to the elevated incidence rate of cytomegalovirus infection, North America & Europe was expected to contribute significantly to the cytomegalovirus infection market. According to the Center for Disease Control and Prevention (CDC), in the U.S. and Europe around 80,000 cases of CMV diseases have been reported. Increased cytomegalovirus (CMV) infection prevalence in developing nations and low economic regions will prominently boost the market growth. Asia-Pacific is expected to develop faster due to the large pool of patients and to increase the incidence of numerous infectious diseases and to increase awareness of cytomegalovirus infections. There were 9,691 incident cases of CMV disease diagnosed in the 7MM in 2017. The United States had the highest number of instances (5,885), while Japan had the lowest (271). According to a research study in India, about 80%-90% of the adult population has CMV antibodies; however, there are few articles indicating the incidence of CMV in pregnant females. Cytomegalovirus antibodies are highly prevalent among blood donors at the NBTS, with nearly all blood donors being exposed to the virus. In India, the extrapolated cytomegalovirus incidence statistics are 532,535,303 of the total population.
Cytomegalovirus infection therapy industry is primarily driven by increased incidence of CMV diseases, increased awareness of herpes disease, pipeline drugs that are promising for the therapy of CMV infection by important market players. In addition, increased public assistance and healthcare infrastructure development are expected to boost the growth of the market for CMV infection. However, latest patented drug expiries, generic drugs available for therapy such as Ganciclovir & Foscarnet are expected to hamper the development of cytomegalovirus infection therapy in the industry.
Table of Content
- Research Methodology
- Executive Summary
- Market Overview
- Industry Insights
- Cytomegalovirus Infection Market, by Drug Type
- Cytomegalovirus Infection Market, by Distribution Channel
- Cytomegalovirus Infection Market, by Region
- Competitive Landscape
Read Other Reports from our Database :
Wise Guy Reports is part of the Wise Guy Research Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available. We also provide COTS (Commercial off the Shelf) business sector reports as custom exploration agreeing your particular needs.
Ph: +162 825 80070 (US)
Ph: +44 203 500 2763 (UK)